Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines

The Oncologist(2020)10.1002/onco.13552Source: DataRank Database

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines is a research paper published in The Oncologist (2020). On theSindex it has a DataRank of 0. It has been cited 67 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access67 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 4.00)OA: bronzeTopics (35)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

V. Sibaud ORCID,Milan J. Anadkat ORCID,Benjamin H. Kaffenberger ORCID,Jonathan S. Leventhal ORCID,Kathleen Guindon

Live enrichment

PubMed:33021006 PMC:PMC7873330 OpenAlex:https://openalex.org/W3091045084

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

FWCI

4.00

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: CC BY NC ND

journalhttps://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/onco.13552

publisherhttps://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/onco.13552

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13552

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/onco.13552

publisherhttps://academic.oup.com/oncolo/article-pdf/26/2/e316/41923658/oncolo_26_2_e316.pdf

Fields of Study

Chronic Myeloid Leukemia TreatmentsCancer Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Antineoplastic AgentsBile Duct NeoplasmsBile Ducts, IntrahepaticHumansMorpholinesPyrimidinesPyrrolesQuality of LifeReceptors, Fibroblast Growth Factor

Keywords

Adverse effectFibroblast growth factor receptorMedicinePharmacologyFibroblast growth factorReceptorInternal medicineGuidelinesDermatologicDrug-related Side Effects And Adverse EventsMorpholinesAntineoplastic AgentsReceptors, Fibroblast Growth FactorBile Ducts, IntrahepaticPyrimidinesBile Duct NeoplasmsSymptom Management and Supportive CareQuality of LifeHumansPyrroles

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being